GNMSF (Genmab AS) Inventory Turnover: 3.33 (As of Mar. 2026)


GNMSF Genmab AS GNMSF
95 GF Score
Price $288.77
GF Value $342.04
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Inventory Turnover?

Genmab AS GNMSF +2.34% 95 Inventory Turnover is 3.33 as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $342.04 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Genmab AS's Cost of Goods Sold for the three months ended in Mar. 2026 was $65 Mil. Genmab AS's Average Total Inventories for the quarter that ended in Mar. 2026 was $20 Mil. Genmab AS's Inventory Turnover for the quarter that ended in Mar. 2026 was 3.33.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Genmab AS's Days Inventory for the three months ended in Mar. 2026 was 27.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genmab AS's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.02.

Genmab AS  (OTCPK:GNMSF) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genmab AS's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=19.5/65*365 / 4
=27.38

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genmab AS's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=19.5 / 896
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Genmab AS Inventory Turnover Related Terms

Genmab AS Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Genmab AS's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Inventory Turnover Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 4.13 16.82 17.63

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.56 4.30 5.06 3.33
GNMSF
95GF Score
Genmab AS GNMSF
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Inventory Turnover Calculation

Genmab AS's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=238 / ((9 + 18) / 2 )
=238 / 13.5
=17.63

Genmab AS's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=65 / ((18 + 21) / 2 )
=65 / 19.5
=3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 3.33 mean?
Genmab AS (GNMSF) has a Inventory Turnover of 3.33 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Genmab AS and its competitors.
Is Genmab AS's Inventory Turnover too high?
Genmab AS's current Inventory Turnover is 3.33. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Inventory Turnover compare to VRTX and REGN?
Genmab AS's Inventory Turnover of 3.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Genmab AS and its competitors. Genmab AS's current Inventory Turnover is 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $342.04, compared to a current price of $288.77 — trading 15.6% below its estimated fair value. The current Inventory Turnover is 3.33. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Inventory Turnover is 3.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $288.77 is trading 15.6% below its estimated GF Value™ of $342.04. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Inventory Turnover: 3.33
  • GF Value™: $342.04 vs. price of $288.77 (15.6% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for GNMSF

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$288.77
Price
$342.04
GF Value